KDC-MN-1353 – Kodiac biolabs

Our opinion on this compoundNiche research probe

46/100

Alpha-7 full agonist reference probe; negative confirmatory schizophrenia trial limits the case but bench utility holds

Look, bradanicline is a genuinely interesting compound for one specific reason: it’s the cleanest, highest-affinity full agonist at the alpha-7 nicotinic acetylcholine receptor anyone has characterized and taken into humans. That 1.4 nanomolar Ki and 80 to 90 percent intrinsic efficacy relative to acetylcholine maximum puts this compound in a different pharmacological stratum than tropisetron or encenicline, both of which are partial agonists with substantially lower efficacy at the receptor. The medicinal chemistry question bradanicline was built to answer, whether higher intrinsic alpha-7 activity translates to better cognitive and negative-symptom outcomes, is a legitimate scientific question. The quinuclidine benzofuran-2-carboxamide scaffold achieves greater than 100-fold selectivity over alpha-4-beta-2 and alpha-3-beta-4 subtypes, so the signal is clean.

Here’s the problem: the answer, at least for schizophrenia cognition, appears to be no. The Lieberman 2013 exploratory trial in 185 patients over 12 weeks at 5 milligrams once daily showed some real signal, statistically significant improvement on the Groton Maze Learning Task and SANS scores, with a particularly interesting working memory effect concentrated in tobacco-using subjects. Thats not nothing. But the Walling 2016 confirmatory trial, 477 outpatients across 64 sites, 24 weeks, two dose levels, came back negative across the board. That was the adequately powered, multi-site answer to the cognitive hypothesis, and it didn’t hold.

What the Targacept program did establish is a clean safety record. Bradanicline did not produce the severe gastrointestinal toxicity that triggered the September 2015 FDA clinical hold on encenicline. For bench investigators choosing which alpha-7 full agonist probe to work with, that distinction is not trivial. The compound has a second life at Anvylic Therapeutics as ATA-101, now targeting Tourette syndrome, which is mechanistically coherent: alpha-7 nicotinic signaling in striatal circuits has a plausible connection to tic regulation. But that program is early and we dont have Phase 2 data yet to score against.

For a bench scientist, the real value here is as a reference standard for alpha-7 pharmacology work. You want to interrogate full agonist versus partial agonist effects on downstream JAK2/STAT3 signaling, on anti-inflammatory NF-kappa-B suppression, on calcium flux and desensitization kinetics in heterologous systems? Bradanicline is your compound. It’s commercially available at greater than 98 percent purity from multiple suppliers, the human PK profile is well-characterized, and the Phase 1 and Phase 2 safety record is solid. That’s a real instrument with real documentation behind it.

We’d place bradanicline in the niche-probe tier rather than established-active because the primary clinical hypothesis has been answered negatively in a well-powered trial, and what remains is pharmacological tool value for investigators whose program is explicitly about alpha-7 receptor biology, full agonist receptor theory, or the Tourette syndrome indication. Deprioritize unless your research question lives squarely in one of those spaces.

Novelty: 38
Mechanism promise: 48
In-category differentiation: 52
Evidence quality: 50
Translational signal: 33
Research bench value: 63

Rationale Bradanicline’s principal value is as the highest-affinity full agonist at alpha-7 nAChR with human PK data and a clean safety record versus encenicline; the Walling 2016 confirmatory trial (n=477, 64 sites, 24 weeks) was negative for cognition and negative symptoms in schizophrenia, decisively limiting translational score, while the full-agonist pharmacological question and the early Tourette syndrome angle preserve niche bench relevance.

Selective alpha-7 nicotinic acetylcholine receptor full agonist

A quinuclidine benzofuran-2-carboxamide developed at Targacept as a selective alpha-7 nicotinic full agonist with a binding affinity of 1.4 nanomolar at the human alpha-7 receptor, advanced through Phase 2 development for cognitive impairment and negative symptoms of schizophrenia with a positive 12-week exploratory trial followed by a negative larger 24-week confirmatory trial, subsequently licensed to Anvylic Therapeutics for Tourette syndrome and other indications.

Abstract

Bradanicline (development codes TC-5619 and ATA-101) is a small-molecule, highly selective full agonist of the homopentameric alpha-7 subtype of the neuronal nicotinic acetylcholine receptor (alpha-7 nAChR), originated at Targacept Pharmaceuticals (Winston-Salem, North Carolina) from a quinuclidine benzofuran-2-carboxamide chemistry program in the mid-2000s and advanced through Phase 1 and Phase 2 clinical development for cognitive impairment associated with schizophrenia. The compound binds the human alpha-7 nicotinic receptor with a Ki of approximately 1.4 nanomolar, slightly higher affinity than encenicline (Ki approximately 4 nanomolar) and substantially higher affinity than tropisetron at the alpha-7 site, and exhibits functional intrinsic activity of approximately 80 to 90 percent of the acetylcholine maximum response in heterologous expression systems, placing it in the high-efficacy stratum of alpha-7 ligands as a full agonist rather than the partial-agonist class that encenicline and tropisetron occupy. The full-agonist intrinsic activity is the principal medicinal-chemistry differentiator of bradanicline within the broader quinuclidine-amide chemical class. Selectivity over alpha-4-beta-2, alpha-3-beta-4, alpha-3-beta-2, and other neuronal nicotinic subtypes is approximately 100-fold or greater. The compound was advanced through an exploratory Phase 2 trial in 185 schizophrenia patients (Lieberman et al. 2013) at 5 milligrams once daily for 12 weeks, with statistically significant improvement on the Groton Maze Learning Task and on the Scale for Assessment of Negative Symptoms compared to placebo, and a statistically significant drug effect on working memory in the tobacco-using subgroup. A larger confirmatory Phase 2 trial (Walling et al. 2016) in 477 schizophrenia outpatients across 64 sites at 5 or 50 milligrams once daily for 24 weeks did not support a benefit on negative or cognitive symptoms compared to placebo. Targacept terminated the cognitive impairment program in 2013 and the compound was subsequently licensed to Catalyst Biosciences and to Anvylic Therapeutics for Tourette syndrome and selected other neurological indications. The compound represents a useful research-clinical reference for the alpha-7 nicotinic full-agonist class and for the assessment of whether higher functional intrinsic activity at the receptor produces greater clinical benefit. Bradanicline did not produce the severe gastrointestinal toxicity that triggered the September 2015 FDA clinical hold on encenicline; the safety profile in Phase 2 was well-tolerated with no clinically noteworthy findings reported. The compound is supplied as a research-grade reagent (greater than 98 percent purity) by multiple chemical suppliers and continues to serve as a reference alpha-7 nicotinic full agonist for fundamental pharmacology research. This monograph reviews the chemistry, synthesis, and stereochemistry of bradanicline; the receptor pharmacology in detail; the human pharmacokinetic record; the indication-by-indication clinical evidence base; and a structured comparative assessment of five alpha-7 nicotinic acetylcholine receptor candidates against bradanicline on five competency standards.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1353Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Tag: KDC-MN-1353

Bradanicline

Abstract

Read the full monograph